Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 2084-2092

  Petraitiene, Ruta ^a,b   Petraitis, Vidmantas ^a,b   Kelaher, Amy M ^a   Sarafandi, Alia A ^a   Mickiene, Diana ^a   Groll, Andreas H ^a,d   Sein, Tin ^a   Bacher, John ^c   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; 2 AMINOCYCLOPENTANECARBOXYLIC ACID; AMPHOTERICIN B; CEFTAZIDIME; CREATININE; CYTARABINE; FLUCONAZOLE; ICOFUNGIPEN; ISOLEUCINE TRANSFER RNA LIGASE INHIBITOR; PHTHALALDEHYDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLASTOCONIDIA; BRAIN; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CAVA VEIN; CENTRAL NERVOUS SYSTEM INFECTION; CONCENTRATION RESPONSE; CONIDIUM; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FLUORESCENCE; FUNGUS GROWTH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LUNG; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE DIAGNOSIS; RABBIT; SPLEEN; UREA NITROGEN BLOOD LEVEL; VITREOUS BODY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CULTURE MEDIA; CYCLOLEUCINE; FEMALE; IMMUNOSUPPRESSION; ISOLEUCINE-TRNA LIGASE; KIDNEY; LIVER; NEUTROPENIA; RABBITS; SPLEEN;

EID: 18244365572     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.2084-2092.2005     Document Type: Article

References (39)

1. Benjamin, D. K., Jr., E. R. DeLong, W. J. Steinbach, C. M. Cotton, T. J. Walsh, and R. H. Clark. 2003. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 112:543-547.
2. Cole, G. T., K. R. Seshan, M. Phaneuf, and K. T. Lynn. 1991. Chlamydospore-like cells of Candida albicans in the gastrointestinal tract of infected, immunocompromised mice. Can. J. Microbiol. 37:637-646.
3. Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891.
4. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
5. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40:1298-1302.
6. Dorrell, S. 2002. Overcoming drug-resistant yeast infections. Drug Discov. Today 7:332-333.
7. Edmond, M. B., S. E. Wallace, D. K. McClish, M. A. Pfaller, R. N. Jones, and R. P. Wenzel. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. CUn. Infect. Dis. 29:239-244.
8. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. 2nd ed., p. 455-459. Marcel Dekker, New York, N.Y.
9. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10:1545-1558.
10. Hobson, R. P. 2003. The global epidemiology of invasive Candida infections-is the tide turning? J. Hosp. Infect. 55:159-168.
11. Jarvis, W. R. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20:1526-1530.
12. Johnson, M. D., and J. R. Perfect. 2003. Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. 4:807-823.
13. Kartsonis, N. A., J. Nielsen, and C. M. Douglas. 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist. Updat. 6:197-218.
14. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
15. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
16. Lewis, R. E., and M. E. Klepser. 1999. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapv. Am. J. Health Syst. Pharm. 56:525-535.
17. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554.
18. Mittendorf, J., F. Klinisch, M. Matzke, H. C. Militzer, A. Schmidt, and W. Schonfeld. 2003. Novel antifungal beta-amino acids: synthesis and activity against Candida albicans. Bioorg. Med. Chem. Lett. 13:433-436.
19. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
21. Odds, F. C. 2000. Pathogenic fungi in the 21st century. Trends Microbiol. 8:200-201.
22. Ostrosky-Zeichner, L., J. H. Rex, J. Bennett, and B. J. Kullberg. 2002. Deeply invasive candidiasis. Infect. Dis. Clin. N. Am. 16:821-835.
23. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, W. E. Dismukes, and NIAID Mycoses Study Group. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
24. Petraitiene, R., V. Petraitis, A. H. Groll, M. Candelario, T. Sein, A. Bell, C. A. Lyman, C. L. McMillian, J. Bacher, and T. J. Walsh. 1999. Antifungal activity of LY303366, a novel echinocandin B. in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43:2148-2155.
25. Petraitis, V., R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
26. Pfaller, M. A. 2000. Epidemiology of nosocomial candidiasis: the importance of molecular typing. Braz. J. Infect. Dis. 4:161-167.
27. Pfaller, M. A., and D. J. Diekema. 2002. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40:3551-3557.
28. Raad, I., H. Hanna, M. Boktour, E. Girgawy, H. Danawi, M. Mardani, D. Kontoyiannis, R. Darouiche, R. Hachem, and G. P. Bodey. 2004. Management of central venous catheters in patients with cancer and candidemia. Clin. Infect. Dis. 38:1119-1127.
29. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
30. Uzun, O., S. Ascioglu, E. J. Anaissie, and J. H. Rex. 2001. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis. 32:1713-1717.
31. Walsh, T. J. 2002, Echinocandins-an advance in the primary treatment of invasive candidiasis. N. Engl. J. Med. 347:2070-2072.
32. Walsh, T. J., C. McEntee, and D. M. Dixon. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
33. Walsh, T. J., J. Bacher, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-470.
34. Walsh, T. J., J. W. Lee, P. Kelly, J. Bacher, J. Lecciones, V. Thomas, C. Lyman, D. Coleman, R. Gordee, and P. A. Pizzo. 1991. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. 35:1321-1328.
35. Walsh, T. J., G. Melcher, M. Rinaldi, J. Lecciones, D. McGough, J. Lee, D. Callender, M. Rubin, and P. A. Pizzo. 1990. Trichosporon beigelli: an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28:1616-1622.
36. Walsh, T. J., and J. H. Rex. 2002. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin. Infect. Dis. 34:600-602.
37. Zaoutis, T. E., H. M. Greves, E. Lautenbach, W. B. Bilker, and S. E. Coffin. 2004. Risk factors for disseminated candidiasis in children with candidemia. Pediatr. Infect. Dis. J. 23:635-641.
38. Ziegelbauer, K. 1998. Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. 42:1581-1586.
39. Ziegelbauer, K., P. Babczinski, and W. Schonfeld. 199S. Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antimicrob. Agents Chemother. 42:2197-2205.